Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Svirshchevskaya, Elena V ^a,b   Mariotti, Jacopo ^b   Wright, Mollie H ^b   Viskova, Natalia Y ^a   Telford, William ^b   Fowler, Daniel H ^b   Varticovski, Lyuba ^b  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; RAPAMYCIN; S6 KINASE; WNT1 PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; WNT1 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MONOTHERAPY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PROTEIN PHOSPHORYLATION; SPLEEN CELL; T CELL DEPLETION; THYMOCYTE; TREATMENT DURATION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL CYCLE; CELL GROWTH; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; LYMPHOCYTE; METHODOLOGY; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; SIROLIMUS; T-LYMPHOCYTES; WNT1 PROTEIN;

EID: 47749125819     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-176     Document Type: Article

References (49)

1. Namba R Young LJ Abbey CK Kim L Damonte P Borowsky AD Qi J Tepper CG MacLeod CL Cardiff RD Gregg JP Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ Clin Cancer Res 2006, 12:2613-2621 10.1158/1078-0432.CCR-05-2170 16638874
2. Teachey DT Obzut DA Cooperman J Fang J Carroll M Choi JK Houghton PJ Brown VI Grupp SA The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL Blood 2006, 107:1149-1155 1895910 16195324 10.1182/blood-2005-05-1935
3. Liu M Howes A Lesperance J Stallcup WB Hauser CA Kadoya K Oshima RG Abraham RT Antitumor activity of Rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer Cancer Res 2005, 65:5325-5336 10.1158/0008-5472.CAN-04-4589 15958580
4. Noh WC Mondesire WH Peng J Jian W Zhang H Dong J Mills GB Hung MC Meric-Bernstam F Determinants of Rapamycin sensitivity in breast cancer cells Clin Cancer Res 2004, 10:1013-1023 10.1158/1078-0432.CCR-03-0043 14871980
5. Huang S Houghton PJ Mechanisms of Resistance to Rapamycin Drug Resist Updat 2004, 4:378-391 10.1054/drup.2002.0227
6. Galanis E Buckner JC Maurer MJ Kreisberg JI Ballman K Boni J Peralba JM Jenkins RB Dakhil SR Morton RF Jaeckle KA Scheithauer BW Dancey J Hidalgo M Walsh DJ North Central Cancer Treatment Group Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study J Clin Oncol 2005, 23:5294-5304 10.1200/JCO.2005.23.622 15998902
7. Chan S Scheulen ME Johnston S Mross K Cardoso F Dittrich C Eiermann W Hess D Morant R Semiglazov V Borner M Salzberg M Ostapenko V Illiger HJ Behringer D Bardy-Bouxin N Boni J Kong S Cincotta M Moore L Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23, 5314-5322 10.1200/JCO.2005.66.130 15955899
8. Atkins MB Hidalgo M Stadler WM Logan TF Dutcher JP Hudes GR Park Y Liou SH Marshall B Boni JP Dukart G Sherman ML Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of Rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 2004, 22:909-918 10.1200/JCO.2004.08.185 14990647
9. Mullins M Perreard L Quackenbush JF Gauthier N Bayer S Ellis M Parker J Perou CM Szabo A Bernard PS Agreement in Breast Cancer Classification between Microarray and Quantitative Reverse Transcription PCR from Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Tissues Clin Chem 2007, 53:1273-1279 10.1373/clinchem.2006.083725 17525107
10. Li Y Hively WP Varmus HE Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer Oncogene 2000, 19:1002-1009 10.1038/ sj.onc.1203273 10713683
11. Li Y Welm B Podsypanina K Huang S Chamorro M Zhang X Rowlands T Egeblad M Cowin P Werb Z Tan LK Rosen JM Varmus HE Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells Proc Natl Acad Sci USA 2003, 100:15853-15858 307657 14668450 10.1073/pnas.2136825100
12. Haritunians T Mori A O'Kelly J Luong QT Giles FJ Koeffler HP Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma Leukemia 2007, 21:333-339 10.1038/sj.leu.2404471 17136116
13. Duran I Kortmansky J Singh D Hirte H Kocha W Goss G Le L Oza A Nicklee T Ho J Birle D Pond GR Arboine D Dancey J Aviel-Ronen S Tsao MS Hedley D Siu LL A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 2006, 95:1148-1154 10.1038/sj.bjc.6603419 17031397
14. Inoki K Guan KL Complexity of themTOR signaling network Trends Cell Biol 2006, 16:206-212 10.1016/j.tcb.2006.02.002 16516475
15. Wanner K Hipp S Oelsner M Ringshausen I Bogner C Peschel C Decker T Mammalian target of Rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab Br J Haematol 2006, 134:475-484 10.1111/ j.1365-2141.2006.06210.x 16856892
16. Creighton CJ A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors Oncogene 2007, 26:4648-4655 10.1038/ sj.onc.1210245 17213801
17. Zheng B Shorthouse R Masek MA Berry G Billingham ME Morris RE Effects of the new and highly active immunosuppressant, Rapamycin, on lymphoid tissues and cells in vivo Transplant Proc 1991, 23:851-855 1703717
18. Tian L Lu L Yuan Z Lamb JR Tam PK Acceleration of apoptosis in CD4+CD8+ thymocytes by Rapamycin accompanied by increased CD4+CD25+ T cells in the periphery Transplantation 2004, 77:183-189 10.1097/ 01.TP.0000101005.44661.3E 14742978
19. Luo H Duguid W Chen H Maheu M Wu J The effect of Rapamycin on T cell development in mice Eur J Immunol 1994, 24:692-701 10.1002/ eji.1830240331 8125138
20. Zheng Y Collins SL Lutz MA Allen AN Kole TP Zarek PE Powell JD A role for mammalian target of Rapamycin in regulating T cell activation versus anergy J Immunol 2007, 178:2163-2170 17277121
21. Battaglia M Stabilini A Migliavacca B Horejs-Hoeck J Kaupper T Roncarolo MG Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients J Immunol 2006, 177:8338-8347 17142730
22. Qu Y Zhang B Zhao L Liu G Ma H Rao E Zeng C Zhao Y The effect of immunosuppressive drug Rapamycin on regulatory CD4(+)CD25(+)Foxp3(+)T cells in mice Transpl Immunol 2007, 17:153-161 10.1016/ j.trim.2007.01.002 17331841
23. Blazar BR Taylor PA Panoskaltsis-Mortari A Vallera DA Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines J Immunol 1998, 160:5355-5365 9605135
24. Mashino K Sadanaga N Tanaka F Ohta M Yamaguchi H Mori M Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: The critical role of Th1-dominant immunity Mol Cancer Ther 2002, 1:785-794 12492111
25. Ikeda H Chamoto K Tsuji T Suzuki Y Wakita D Takeshima T Nishimura T The critical role of type-1 innate and acquired immunity in tumor immunotherapy Cancer Sci 2004, 95:697-703 10.1111/ j.1349-7006.2004.tb03248.x 15471553
26. Jung U Foley JE Erdmann AA Toda Y Borenstein T Mariotti J Fowler DH Ex vivo Rapamycin generates Th1/Tc1 or Th2/Tc2 effector T cells with enhanced in vivo function and differential sensitivity to post-transplant Rapamycin therapy Biol Blood Marrow Transplant 2006, 12:905-918 10.1016/j.bbmt.2006.05.014 16920556
27. Varticovski L Hollingshead MG Robles AI Wu X Cherry J Munroe DJ Lukes L Anver MR Carter JP Borgel SD Stotler H Bonomi CA Nunez NP Hursting SD Qiao W Deng CX Green JE Hunter KW Merlino G Steeg PS Wakefield LM Barrett JC Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models Clin Cancer Res 2007, 13:2168-2177 10.1158/1078-0432.CCR-06-0918 17404101
28. Robles AI Varticovski L Harnessing genetically engineered mouse models for preclinical testing Chem Biol Interact 2007 doi:10.1016. 17362899
29. Nunez N Perkins S Smith N Berrigian D Varticovski L Hursting S Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones Nutrition and Cancer 2008
30. Ozgen U Savasan S Buck S Ravindranath Y Comparison of DiOC(6)(3) uptake and annexin V labeling for quantification of apoptosis in leukemia cells and non-malignant T lymphocytes from children Cytometry 2000, 42:74-78 10.1002/(SICI)1097-0320(20000215)42:1<74::AID-CYTO11>3.0.CO;2-6 10679746
31. Strauss L Whiteside TL Knights A Bergmann C Knuth A Zippelius A Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin J Immunol 2007, 178:320-329 17182569
32. Marimpietri D Brignole C Nico B Pastorino F Pezzolo A Piccardi F Cilli M Di Paolo D Pagnan G Longo L Perri P Ribatti D Ponzoni M Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis Clin Cancer Res 2007, 13:3977-3988 10.1158/1078-0432.CCR-06-2757 17606732
33. Libetta C Sepe V Zucchi M Portalupi V Meloni F Rampino T Dal Canton A The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo Kidney Int 2007, 72:114-120 10.1038/ sj.ki.5002255 17410097
34. Quesniaux VF Wehrli S Steiner C Joergensen J Schuurman HJ Herrman P Schreier MH Schuler W The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo Blood 1994, 84:1543-1552 7520778
35. Tamiolakis D Simopoulos C Cheva A Lambropoulou M Kotini A Jivannakis T Papadopoulos N Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast Eur J Gynaecol Oncol 2002, 23:433-436 12440819
36. Bilik R Mor C Hazaz B Moroz C Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer Cancer Immunol Immunother 1989, 28:143-147 10.1007/BF00199115 2783889
37. Hackstein H Taner T Zahorchak AF Morelli AE Logar AJ Gessner A Thomson AW Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo Blood 2003, 101:4457-4463 10.1182/blood-2002-11-3370 12531798
38. Wiederrecht GJ Sabers CJ Brunn GJ Martin MM Dumont FJ Abraham RT Mechanism of action of Rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells Prog Cell Cycle Res 1995, 1:53-71 9552353
39. Sarbassov DD Ali SM Sengupta S Sheen JH Hsu PP Bagley AF Markhard AL Sabatini DM Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 2006, 22:159-168 10.1016/j.molcel.2006.03.029 16603397
40. Ribatti D Nico B Mangieri D Longo V Sansonno D Vacca A Dammacco F In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and Rapamycin Histol Histopathol 2007, 22:285-289 17163402
41. Kwon YS Hong HS Kim JC Shin JS Son Y Inhibitory effect of Rapamycin on corneal neovascularization in vitro and in vivo Invest Ophthalmol Vis Sci 2005, 46:454-460 10.1167/iovs.04-0753 15671269
42. Guba M von Breitenbuch P Steinbauer M Koehl G Flegel S Hornung M Bruns CJ Zuelke C Farkas S Anthuber M Jauch KW Geissler EK Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor Nat Med 2002, 8:128-135 10.1038/ nm0202-128 11821896
43. Kuo PL Hsu YL Cho CY Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of Rapamycin pathway in breast cancer cells Mol Cancer Ther 2006, 5:3209-3221 10.1158/ 1535-7163.MCT-06-0478 17172425
44. Takeuchi H Kondo Y Fujiwara K Kanzawa T Aoki H Mills GB Kondo S Synergistic augmentation of Rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors Cancer Res 2005, 65:3336-3346 15833867
45. Brown AM Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Res 2001, 3:351-355 138699 11737884 10.1186/bcr321
46. Longo KA Kennell JA Ochocinska MJ Ross SE Wright WS MacDougald OA Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors J Biol Chem 2002, 277:38239-38244 10.1074/ jbc.M206402200 12154096
47. Chen S Guttridge DC You Z Zhang Z Fribley A Mayo MW Kitajewski J Wang CY Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription J Cell Biol 2001, 152:87-96 2193656 11149923 10.1083/jcb.152.1.87
48. Martin JL Baxter RC Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway Endocrinology 2007, 148:2532-2541 10.1210/en.2006-1335 17289850
49. Inoki K Ouyang H Zhu T Lindvall C Wang Y Zhang X Yang Q Bennett C Harada Y Stankunas K Wang CY He X MacDougald OA You M Williams BO Guan KL TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth Cell 2006, 126:955-968 10.1016/ j.cell.2006.06.055 16959574